Tharimmune Strengthens Leadership with Key Appointments

Tharimmune, Inc., a clinical-stage biotechnology company listed on NASDAQ, has announced pivotal changes to its leadership team. Sireesh Appajosyula has assumed the role of Chief Executive Officer, bringing vast industry experience to his new position. Appajosyula previously served as Chief Operating Officer and has held significant roles in other biotech firms.

The company also appointed Vincent LoPriore as Executive Chairman of the Board of Directors. LoPriore has an extensive background in investment banking, focusing on capital raising and regulatory processes. His leadership is expected to enhance Tharimmune's strategic objectives.

Moreover, James Gordon Liddy, former US Navy SEAL Commander, has joined the board. His expertise in national security will be vital as Tharimmune advances its lead project, TH104, aimed at countering opioid-related threats.